[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337801-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337801-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-novel-approaches-in-the-systemic-therapy-of-low-grade-serous-carcinoma-of-the-ovary-a-literature-review","Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary - a literature review","","Comprehensive analysis of low-grade serous carcinomas (LGSCs), an epithelial ovarian cancer subset, detailing molecular characteristics, clinicopathological features, and systemic therapy options. The review highlights frequent activation of the RAS/RAF/MEK/MAPK pathway, common KRAS and BRAF mutations, and rare p53 mutations, alongside lower chemosensitivity than high-grade serous carcinomas. It discusses endocrine maintenance approaches, and novel strategies using CDK4/6 inhibitors, MEK inhibitors, and antiangiogenic agents such as bevacizumab.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-novel-approaches-in-the-systemic-therapy-of-low-grade-serous-carcinoma-of-the-ovary-a-literature-review/337801/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-novel-approaches-in-the-systemic-therapy-of-low-grade-serous-carcinoma-of-the-ovary-a-literature-review/337801.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What molecular features characterize low-grade serous carcinoma in this review?","Question",{"text":63,"@type":64},"Low-grade serous carcinomas show prevalent RAS/RAF/MEK/MAPK pathway activation, frequent KRAS and BRAF mutations, and infrequent p53 mutations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does treatment responsiveness of LGSC compare with high-grade serous carcinoma?",{"text":68,"@type":64},"Chemotherapy is commonly used, but LGSC demonstrates lower responsiveness than high-grade serous carcinoma.",{"name":70,"@type":61,"acceptedAnswer":71},"Which novel systemic therapy approaches are explored for LGSC?",{"text":72,"@type":64},"The review investigates CDK4/6 inhibitors, MEK inhibitors, and antiangiogenic therapy such as bevacizumab, along with hormone therapy including endocrine maintenance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337801,1790355127,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","TYPE Review  \nPUBLISHED 21 May 2024  \nDOI 10.3389/fmed.2024.1366603  \nOPEN ACCESS  \nEDITED BY  \nA. Seval Ozgu-Erdinc,  \nAnkara City Hospital, Türkiye  \nREVIEWED BY  \nZhaochu Wang,  \nThe Afﬁliated People’s Hospital of Fujian University of Traditional Chinese Medicine,  \nChina  \nCristiano de Pádua Souza, Barretos Cancer Hospital, Brazil  \n*CORRESPONDENCE  \nGiovanna Vieira Giannecchini  \n [giovannavg.92@gmail.com](giovannavg.92@gmail.com)  \nRECEIVED 06 January 2024  \nACCEPTED 26 April 2024  \nPUBLISHED 21 May 2024  \nCITATION  \nGiannecchini GV,  \nda Silva JL,de Oliveira Bretas G, dos Santos ALS, Baltar LFR and de Melo AC (2024) Exploring novel approaches  \nin the systemic therapy of low-grade serous carcinoma of the ovary: a literature review.  \nFront. Med. 11:1366603 .  \ndoi: 10.3389/fmed.2024.1366603  \nCOPYRIGHT  \n© 2024 Giannecchini, da Silva, de Oliveira Bretas, dos Santos, Baltar and de Melo. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nExploring novel approaches in the systemic therapy of  \nlow-grade serous carcinoma of the ovary: a literature review  \nGiovanna Vieira Giannecchini*, Jessé Lopes da Silva, Gustavo de Oliveira Bretas,  \nAlexssandra Lima Siqueira dos Santos,  \nLais Fernandes Rodrigues Baltar and Andreia Cristina de Melo Oncoclínicas&Co – Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil  \nBy presenting a comprehensive analysis of low-grade serous carcinomas (LGSCs), a subset of epithelial ovarian cancers, this review delves into their distinct molecular characteristics, clinicopathological features and systemic therapy options, emphasizing their differences from high-grade serous carcinomas (HGSCs) . Notably, LGSCs exhibit prevalent RAS/RAF/MEK/MAPK pathway activation, KRAS and BRAF mutations, and infrequent p53 mutations. While chemotherapy is commonly employed, LGSCs display lower responsiveness compared to HGSCs. Hormone therapy, particularly endocrine maintenance therapy, is explored due to the higher estrogen receptor expression. Novel therapeutic approaches involving CDK4/6 inhibitors, MEK inhibitors, and antiangiogenic agents like bevacizumab are also investigated. Ongoing clinical trials are striving to enhance LGSC treatment strategies, offering valuable insights for future therapeutic advancements in this challenging ovarian cancer subtype.  \nKEYWORDS  \novarian cancer, low-grade serous carcinoma, molecular features, systemic treatment, novel therapeutic options  \n1 Introduction  \nOvarian cancer (OC) is the seventh most common cancer in women worldwide (1) . In 2020, approximately 314,000 women were diagnosed with this neoplasm and 207,000 died from the disease (2) .  \nBased on the component from which OC originates, it can be classiﬁed into epithelial carcinoma, germ cell tumor and sex cord-stromal tumor. The most common are the epithelial carcinomas, which accounts for about 90% of ovarian tumors ( 1) .  \nPreviously regarded as a singular entity, epithelial ovarian cancers (EOCs) are now increasingly acknowledged as a diverse collection of tumors encompassing various histologic subcategories. These subtypes are characterized by their unique immunohistochemical, histopathological, and molecular attributes (3) . The main  \nFrontiers in Medicine 01 [frontiersin.org](frontiersin.org)  \nclassiﬁcation of EOCs encompasses ﬁve distinct subtypes, namely high-grade serous carcinomas (HGSCs), endometrioid carcinomas, clear-cell carcinomas, mucinous carcinomas, and low-grade serous carcinomas (LGSCs) (4) . In contrast to HGSCs, which constitute approximately 70􀂖80% of all malignant ovarian tumors, LGSC","cbCaifDurmuBZY7N","https://ap.wps.com/l/cbCaifDurmuBZY7N","pdf",787681,"English","# Introduction\n## Pathology","[{\"question\":\"What molecular features characterize low-grade serous carcinoma in this review?\",\"answer\":\"Low-grade serous carcinomas show prevalent RAS/RAF/MEK/MAPK pathway activation, frequent KRAS and BRAF mutations, and infrequent p53 mutations.\"},{\"question\":\"How does treatment responsiveness of LGSC compare with high-grade serous carcinoma?\",\"answer\":\"Chemotherapy is commonly used, but LGSC demonstrates lower responsiveness than high-grade serous carcinoma.\"},{\"question\":\"Which novel systemic therapy approaches are explored for LGSC?\",\"answer\":\"The review investigates CDK4/6 inhibitors, MEK inhibitors, and antiangiogenic therapy such as bevacizumab, along with hormone therapy including endocrine maintenance.\"}]","Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary - a literature review | PDF",1790020700,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ce2818d94ffe387d018b0885cacba91.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c73bc25f5e0d5e7af7d793c569bda72f.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1926a68d6d1eecdb771a535a4f0ba652.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dae06747fa73a48325cf02b44a9b807.webp",980,1385]